

Parkinson's Disease - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P87158B393FEN.html>

Date: April 2020

Pages: 1201

Price: US\$ 2,500.00 (Single User License)

ID: P87158B393FEN

Abstracts

Parkinson's Disease - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Pipeline Review, H1 2020, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 47, 58, 4, 212, 90 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 51 and 15 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Parkinson's Disease - Overview

Parkinson's Disease - Therapeutics Development

Parkinson's Disease - Therapeutics Assessment

Parkinson's Disease - Companies Involved in Therapeutics Development

Parkinson's Disease - Drug Profiles

Parkinson's Disease - Dormant Projects

Parkinson's Disease - Discontinued Products

Parkinson's Disease - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Parkinson's Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Parkinson's Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

1st Bio Therapeutics Inc
4D Pharma Plc
Abaxy Sprl
AbbVie Inc
Abivax SA
ABL Bio Inc
AC Immune SA
Acelot Inc
AcuraStem Inc
Addex Therapeutics Ltd
Affichem SA
AFFiRiS AG
AgoneX Biopharmaceuticals Inc
Alan Laboratories Inc
Alector Inc
Alectos Therapeutics
Alexza Pharmaceuticals Inc
Alkahest Inc
Alkermes Plc
Allife Medical Science and Technology Co Ltd
AlphaCognition Inc

Alsonex Pty Ltd
Alterity Therapeutics Ltd
Amabiotics SAS
Amathus Therapeutics Inc
Amneal Pharmaceuticals Inc
Anavex Life Sciences Corp
Anida Pharma Inc
Annovis Bio Inc
Antoxis Ltd
Aoxing Pharmaceutical Company Inc
Apollo Therapeutics LLC
Appello Pharmaceuticals Inc
Aprinoia Therapeutics Inc
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Araclon Biotech SL
Aranda Pharma Ltd
AriBio
ArmaGen Inc
Arrien Pharmaceuticals LLC
Arvinas Inc
Asdera LLC
Asklepios BioPharmaceutical Inc
Aspen Neuroscience Inc
Astellas Pharma Inc
AstraZeneca Plc
Athersys Inc
Athira Pharma Inc
Auritec Pharmaceuticals Inc
Avicanna Inc
Axial Biotherapeutics Inc
Axovant Gene Therapies Ltd
AZTherapies Inc
Azymus Therapeutics Inc
B&A Therapeutics
BCWorld Pharm Co Ltd
Belrose Pharma Inc
Berg LLC
Better Life Pharmaceuticals Inc

Bial - Portela & Ca SA
Bio-Modeling Systems SAS
Bio-Pharm Solutions Co Ltd
Bioasis Technologies Inc
Biogen Inc
BlueRock Therapeutics
BrainStorm Cell Therapeutics Inc
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Calico LLC
Califia Bio Inc
Cantabio Pharmaceuticals Inc
Canvax Biotech SL
Capo Therapeutics Inc
Carmot Therapeutics Inc
Carna Biosciences Inc
Cavion LLC
CavoGene LifeSciences
Celavie Biosciences LLC
CellCure
Cellivory Therapeutics Inc
Cellix Bio Pvt Ltd
Cerecin Inc
Cerecor Inc
CereSpir Inc
Cerevance Inc
Cerevel Therapeutics LLC
CHA Biotech Co Ltd
Chase Therapeutics Corp
Chiesi Farmaceutici SpA
Chipscreen Biosciences Ltd
CholesteniX Ltd
Chongqing Pharmaceutical Research Institute Co Ltd
Ci Therapeutics
Clayton Biotechnologies Inc
Clene Nanomedicine Inc
Clevexel Pharma SAS
Cogentis Therapeutics Inc
Collaborative Medicinal Development LLC

Contera Pharma ApS
Copernicus Therapeutics Inc
Corium, Inc.
Crossject SA
CuraSen Therapeutics Inc
Curemark LLC
CuroNZ Ltd
Curyx Bio Inc
Cypralis Ltd
Dadang & BIO Co Ltd
DanPET AB
Declion Pharmaceuticals Inc
DegenRx BV
Denali Therapeutics Inc
DermaXon LLC
Diffusion Pharmaceuticals Inc
Dina Pharmaceuticals Inc
Dizlin Medical Design AB
Domain Therapeutics SA
DongKoo Bio & Pharma Co Ltd
E-scape Bio Inc
Easywell Biomedical Inc
Eisai Co Ltd
Eli Lilly and Co
Emerald Health Sciences Inc
Emerald Organic Products Inc
Energenesis Biomedical Co Ltd
Evgen Pharma Plc
Fabre-Kramer Pharmaceuticals Inc
Fortuna Fix Inc
Fulcrum Therapeutics Inc
GB Sciences Inc
Generoath Co Ltd
Genervon Biopharmaceuticals LLC
GenKyoTex SA
Genmab AS
Genzyme Corp
Gismo Therapeutics Inc
Global BioLife Inc Ltd

GNT Pharma Co Ltd
Grespo AB
GT Gain Therapeutics SA
Guangzhou Magpie Pharmaceutical Co Ltd
H. Lundbeck AS
Hebei Newtherapy Bio-Pharma Technology Co Ltd
Herantis Pharma Plc
HitGen LTD
Hong Kong WD Pharmaceutical Co Ltd
Hope Biosciences LLC
Icagen Inc
ICB International Inc
Icure Pharmaceutical Inc
Imago Pharmaceuticals Inc
Immune Modulation Inc
Immugenetics AG
Impel NeuroPharma Inc
Inexia Ltd
Inflazome Ltd
Inhibikase Therapeutics Inc
InnoMedica Holding AG
Intec Pharma Ltd
International Stem Cell Corp
Intra-Cellular Therapies Inc
Invisio Ltd
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
IRLAB Therapeutics AB
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Junaxo Inc
Kainos Medicine Inc
Kariya Pharmaceuticals IVS
Kashiv BioSciences LLC
Keapstone Therapeutics Ltd
Kissei Pharmaceutical Co Ltd
Kyowa Kirin Co Ltd
Lauren Sciences LLC
Lead Discovery Center GmbH

Living Cell Technologies Ltd
Longevity Biotech Inc
Luye Pharma Group Ltd
Lysosomal Therapeutics Inc
Macrobian Biotech BV
Mavalon Therapeutics Ltd
MD Healthcare Inc
Med-Life Discoveries LP
MedGenesis Therapeutix Inc
MeiraGTx Holdings Plc
Merck & Co Inc
Meta-IQ ApS
Metabolic Solutions Development Company LLC
MetiMedi Pharmaceuticals Co Ltd
MetVital Inc
MimeTech Srl
Minerva Neurosciences Inc
Mission Therapeutics Ltd
Mitochon Pharmaceuticals Inc
Mitoconix Bio Ltd
MitoDys Therapeutics Ltd
Mitokinin LLC
Mitsubishi Tanabe Pharma Corp
Modag GmbH
Montisera Ltd
Motac Neuroscience Ltd
Neonc Technologies Inc
Netherlands Translational Research Center BV
NeuBase Therapeutics Inc
NeuExcell Therapeutics Inc
Neuracle Science Co Ltd
Neuraly Inc
Neuren Pharmaceuticals Ltd
Neuro Vigor LLC
Neurocea Pharmaceuticals
Neurochlore
Neurodon LLC
Neuroene Therapeutics LLC
NeuroGeneration Inc

Neurona Therapeutics Inc
NeuroNascent Inc
NeuroPn Therapeutics LLC
Neuropore Therapies Inc
Neurotrope Bioscience Inc
New Amsterdam Sciences Inc
New Biotic Inc
New World Laboratories Inc
Newron Pharmaceuticals SpA
Nitrome Biosciences Inc
nLife Therapeutics SL
NLS Pharma Group
Novartis AG
Novo Nordisk AS
NTZ Lab Ltd
NutriBand Inc
Omeros Corp
Oncodesign SA
Orphazyme A/S
Orpheris Inc
Oryzon Genomics SA
Oxyrane Belgium NV
Parkure Ltd
Peptron Inc
Pfizer Inc
Pharma Two B Ltd
Pharmatrophix Inc
Pharmicell Co Ltd
Phoenix Biotechnology Inc
Phoenix Life Sciences International Ltd
PK Biosciences Corp
Plex Pharmaceuticals Inc
Polaryx Therapeutics Inc
PolyCore Therapeutics LLC
Prevail Therapeutics Inc
Priavoid GmbH
Primary Peptides Inc
Proclara Biosciences Inc
ProMIS Neurosciences Inc

Promius Pharma LLC
Prothena Corp Plc
Prous Institute for Biomedical Research SA
Psy Therapeutics Inc
PTC Therapeutics Inc
reMYND NV
Renown Pharmaceuticals Pvt Ltd
resTORbio Inc
Retrotepe Inc
Revaluesio Corp
Rich Pharmaceuticals Inc
Rionis LLC
Sage Therapeutics Inc
SalubRx Therapeutics Inc
SanBio Inc
Sandoz International GmbH
Saniona AB
Sanofi
Seelos Therapeutics, Inc.
Seneb BioSciences Inc
Sengenics International Pte Ltd
Serina Therapeutics Inc
Shanghai Angecon Biotechnology Corp
Shenox Pharmaceuticals LLC
Shift Bioscience Ltd
SignPath Pharma Inc
Sinfonia Biotherapeutics Inc
Sorrento Therapeutics Inc
SparkBioPharma Inc
STATegics Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Suven Life Sciences Ltd
Synthonics Inc
Takeda Pharmaceutical Co Ltd
Tarus Therapeutics Inc
TauRx Therapeutics Ltd
Techfields Pharma Co Ltd

TechnoPhage SA
Teikoku Pharma USA Inc
Tranquis Therapeutics Inc
TreeFrog Therapeutics SAS
Trementis Corp
TruCode Gene Repair Inc
UCB SA
UniQure NV
United Neuroscience Ltd
Varinell Inc
Verge Genomics Inc
Videns Incorp Ltd
Vivreon Biosciences LLC
Voyager Therapeutics Inc
WhanIn Pharmaceutical Co Ltd
Xcelthera INC
Xoc Pharmaceuticals Inc
XYnapse Therapeutics Pty Ltd
Yuhan Corp
Yumanity Therapeutics
Zhittya Genesis Medicine Inc

I would like to order

Product name: Parkinson's Disease - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P87158B393FEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P87158B393FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970